INmune Bio, Inc. Prices Public Offering of Common Stock

Prices Public Offering of Common Stock

JOLLA, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or

"INmune"), a clinical-stage immunology company focused on developing treatments that harness a patient's

innate immune system to fight disease, today announced

today the pricing of its underwritten public offering of an aggregate of 2,173,914 shares of its common stock at a public offering

price of $10.00 per share. In addition, INmune has granted the underwriters an over-allotment option, exercisable for 45 days

from today to purchase up to an additional 326,086 shares of common stock at the public offering price, less

the underwriting discounts and commissions. The offering is expected to close on or about

July 20, 2020, subject to customary closing conditions.

gross proceeds to INmune from this offering are expected to be approximately $21.7 million, before deducting underwriting

discounts and commissions and other offering expenses payable by INmune but excluding any exercise of the underwriters'

option to purchase additional shares of common stock. Net proceeds are estimated to be

$20 million. INmune intends to use the net proceeds from the offering for general corporate purposes, including to

support research and development, including clinical trials.

LLC is acting as sole book-running manager of the offering, and National Securities Corporation is acting as a co-manager.

offering is being made pursuant to the shelf registration statement on Form S-3 (File No. 333-237368) that was filed with the

Securities and Exchange Commission (the "SEC") on March 24, 2020 and became effective on April 2, 2020. The offering

is being made only by means of written prospectuses and prospectus supplements that form part of the registration statements.

Preliminary prospectus supplements and accompanying prospectuses relating to and describing the terms of the offering have been

filed with the SEC and are available on the SEC's website at www.sec.gov. The final prospectus supplements and accompanying

prospectuses for each offering will be filed with the SEC. When available, copies of the final prospectus supplements and accompanying

prospectuses for each offering may be obtained for free from BTIG, LLC, Attention: Equity Capital Markets, 65 East 55th

Street, New York, NY 10022, by telephone at (212) 593-7555 or by email at equitycapitalmarkets@btig.com.

press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be

any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to

the registration or qualification under the securities laws of any such state or jurisdiction.

Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target

the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative

technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases.

DN-TNF is currently being developed for COVID-19 complications (Quellor ), cancer (INB03 ), Alzheimer's (XPro595),

and NASH (LIVNate ). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's

NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision

medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn

more, please visit www.inmunebio.com.

trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this

press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private

Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including without limitation statements

regarding the completion and timing of the offering and the amount and use of proceeds therefrom, are based on current expectations

but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may

differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03 ,

XPro1595, LIVNate, Quellor and INKmune are still in clinical trials or preparing to start clinical trials and have not

been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our

two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that

could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties

relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding

for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;

and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.

These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange

Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the

Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order

to reflect any event or circumstance that may arise after the date of this release.

David Moss, CFO (858) 964-3720

James Carbonara (646) 755-7412